Cite
Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer.
MLA
Gough, Madeline, et al. “Development of a CUB Domain-Containing Protein 1 (CDCP1)-Targeting Antibody-Drug Conjugate for Triple-Negative and Metastatic Breast Cancer.” Journal of Clinical Oncology, vol. 41, June 2023, p. e15012. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.e15012.
APA
Gough, M., Kwah, K., He, Y., Snell, C. E., Hooper, J. D., & Kryza, T. (2023). Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer. Journal of Clinical Oncology, 41, e15012. https://doi.org/10.1200/JCO.2023.41.16_suppl.e15012
Chicago
Gough, Madeline, Kayden Kwah, Yaowu He, Cameron Edward Snell, John D. Hooper, and Thomas Kryza. 2023. “Development of a CUB Domain-Containing Protein 1 (CDCP1)-Targeting Antibody-Drug Conjugate for Triple-Negative and Metastatic Breast Cancer.” Journal of Clinical Oncology 41 (June): e15012. doi:10.1200/JCO.2023.41.16_suppl.e15012.